Scientists at the University of Alabama at Birmingham (UAB) in the US are set to evaluate the potential of a new non-invasive, US Food and Drug Administration (FDA)-cleared technique to assess hematoma expansion in the brain.
Expanding hematomas are ruptured blood vessels in the brain that arise due to traumatic brain injury and are linked to poorer results for individuals.
The UAB team will launch a two-year clinical trial to assess the role of a device called Infrascanner for monitoring brain injury.
The hand-held device has obtained FDA approval to identify traumatic intracranial hematomas.
The trial intends to investigate the usefulness of the device for examining the size of hematomas as well as finding any size variations.
Usually, expanding hematomas need therapy modification.
Leveraging near-infrared spectroscopy, Infrascanner can identify intracranial hematomas based on the differential light absorption by the injured versus the non-injured brain regions.
Furthermore, the device assesses the left and right sides of the brain in four separate regions.
Measurements can be attained in just a few minutes, the UAB team noted.
Collaborating with nine other Level I trauma centres in the US, the CIS Clinical Trials Unit will recruit 400 individuals with intracranial bleeding.
The $2.8m study is funded by the Combat Casualty Care Research Program’s Neurotrauma Program at the US Army Medical Research and Development Command through the Medical Technology Enterprise Consortium.
UAB Center for Injury Science director Jan Jansen said: “We are thrilled to be able to evaluate the role of this exciting new technology in detecting hematoma expansion.
“This may help improve treatment for patients with traumatic brain injuries and may improve outcomes.
“The device allows a medical professional to detect and measure a hematoma quickly and easily, even in a challenging environment.”